LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

LLY

980.55

-1.5%↓

JNJ

243.38

+0.09%↑

ABBV

226.47

-0.69%↓

NVS

154.32

-0.8%↓

AZN

191.82

-0.47%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

21.26 -0.05

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.24

Max

21.28

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-1.97% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.31
Ankstesnė uždarymo kaina	21.26

Naujienos nuotaikos

By Acuity

50%

147 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-11 19:18; UTC

Pagrindinės rinkos jėgos

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

2026-03-11 23:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-11 23:54; UTC

Rinkos pokalbiai

Nikkei May Decline on Energy Costs Concerns -- Market Talk

2026-03-11 23:51; UTC

Rinkos pokalbiai

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

2026-03-11 23:41; UTC

Rinkos pokalbiai

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

2026-03-11 23:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

2026-03-11 23:17; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

2026-03-11 23:17; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

2026-03-11 22:29; UTC

Rinkos pokalbiai

Australia Shares Set to Fall in Early Trade -- Market Talk

2026-03-11 21:47; UTC

Uždarbis

Liontown Resources: Market Tailwinds Strengthening Outlook

2026-03-11 21:46; UTC

Uždarbis

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

2026-03-11 21:45; UTC

Uždarbis

Liontown Resources Says FY26 Guidance Unchanged

2026-03-11 21:45; UTC

Uždarbis

Liontown Resources 1H Unit Operating Costs A$985/Ton

2026-03-11 21:44; UTC

Uždarbis

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

2026-03-11 21:43; UTC

Uždarbis

Liontown Resources 1H Revenue A$207.5 Million

2026-03-11 21:43; UTC

Uždarbis

Liontown Resources 1H Net Loss A$184 Million

2026-03-11 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

2026-03-11 21:10; UTC

Uždarbis

Vista Gold FY25 Loss $7.5M >VGZ

2026-03-11 21:10; UTC

Uždarbis

Vista Gold FY25 Loss/Shr 6c >VGZ

2026-03-11 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-11 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-11 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Papa John's Draws Fresh Takeover Interest -- 2nd Update

2026-03-11 20:26; UTC

Uždarbis

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

2026-03-11 20:19; UTC

Svarbiausios naujienos

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

2026-03-11 20:15; UTC

Uždarbis

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

2026-03-11 20:12; UTC

Svarbiausios naujienos

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

2026-03-11 19:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

2026-03-11 19:01; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

2026-03-11 18:59; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

2026-03-11 18:43; UTC

Svarbiausios naujienos

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-1.97% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -1.97%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

147 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.